CD274 and non-small cell lung carcinoma: The clinical dilemma of choosing the single agent pembrolizumab or a triplet chemotherapy and ICI in advanced NSCLC with a high PD-L1 expression could be avoided if we could distinguish the two subsets before treatment initiation.